Standout Papers

Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial 2024 202676
  1. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial (2024)
    John Deanfield, Subodh Verma et al. The Lancet

Immediate Impact

1 from Science/Nature 59 standout
Sub-graph 1 of 23

Citing Papers

Global, regional, and national burden of atrial fibrillation and atrial flutter from 1990 to 2021: sex differences and global burden projections to 2046—a systematic analysis of the Global Burden of Disease Study 2021
2025 Standout
From Cardiovascular-Kidney-Metabolic Syndrome to Cardiovascular-Renal-Hepatic-Metabolic Syndrome: Proposing an Expanded Framework
2025 Standout

Works of Assen Goudev being referenced

Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial
2024 Standout
Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE–TIMI 58 trial
2021

Author Peers

Author Last Decade Papers Cites
Assen Goudev 244 104 106 35 365
Udo Steigerwald 171 92 66 17 382
Angela Cheng-Lai 140 110 63 31 348
Zi-Xiang Yu 158 108 79 33 374
Arjun Pandey 206 63 152 34 359
José M. Mostaza 115 193 84 30 364
Takashi Hitsumoto 247 130 143 51 386
Ioannis Leontsinis 159 61 87 50 311
Shinji Hisatake 235 80 56 37 309
Miao Yu 109 89 175 27 341
Shin Kawasoe 154 51 92 42 301

All Works

Loading papers...

Rankless by CCL
2026